TOP > 外国特許検索 > MEDICINAL COMPOSITION FOR TREATING AND/OR PREVENTING ESOPHAGEAL STENOSIS

MEDICINAL COMPOSITION FOR TREATING AND/OR PREVENTING ESOPHAGEAL STENOSIS

Foreign code F160008846
File No. S2014-1359-C0
Posted date 2016年9月14日
Country 世界知的所有権機関(WIPO)
International application number 2015JP072385
International publication number WO 2016024524
Date of international filing 平成27年8月6日(2015.8.6)
Date of international publication 平成28年2月18日(2016.2.18)
Priority data
  • 特願2014-164429 (2014.8.12) JP
Title MEDICINAL COMPOSITION FOR TREATING AND/OR PREVENTING ESOPHAGEAL STENOSIS
Abstract Provided is a medicinal composition for treating and/or preventing esophageal stenosis that comprises an HGF protein as an active ingredient, wherein said HGF protein is one of the following polypeptides: (a) a polypeptide comprising an amino acid sequence represented by SEQ ID NO:2; (b) a polypeptide comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:2 by deletion, substitution or addition of one to several amino acids; and (c) a polypeptide comprising an amino acid sequence having a 90% or more identity with the amino acid sequence represented by SEQ ID NO:2. Also provided is a stent that comprises the medicinal composition.
Outline of related art and contending technology BACKGROUND ART
In the esophagus, esophageal cancer at an early stage (superficial esophageal cancer) with respect to the endoscopic submucosal layer peeling is generated at a high rate after surgery is constricted. Post-operative release submucosa such endoscopic esophageal stricture for balloon dilatation is used, difficulty in swallowing such as stenosis of a plurality of times the symptoms require dilatation, can easily be obtained once expanded also often relapse.
As described above with respect to the esophageal stricture of post-surgical release the submucosal layer, other than the endoscopic balloon dilatation effective solution is not known until now.
On the other hand, HGF is, in the year 1986 goda tsubouchi et al. fulminant hepatitis and isolated from the patient's plasma, a growth factor that promotes lung and reproduction (non-patent document 1), the human cDNA is, cloned in the year 1989 (non-patent document 2). Various stem cells as well as HGF epithelial system cells, endothelial cells and some mesenchymal cells such as with a variety of cell proliferation to exert their effect. In addition, alimentary canal mucosa injury HGF factor essential in the repair, repair of mucosal injury-promoting effects, experiments with recombinant human HGF enteritis model has been confirmed (non-patent document 3-5).
However, effective against HGF is intestinal tract stenosis, not known until now.
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • KAGOSHIMA UNIVERSITY
  • Inventor
  • IDO Akio
  • TSUBOUCHI Hirohito
  • KOMAKI Yuga
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
特許の内容に興味を持たれた方、ライセンスをご希望の方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close